These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 10469452

  • 21. Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated.
    Järvinen TA, Liu ET.
    Cytopathology; 2003 Dec; 14(6):309-13. PubMed ID: 14632727
    [Abstract] [Full Text] [Related]

  • 22. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
    Konecny GE, Pauletti G, Untch M, Wang HJ, Möbus V, Kuhn W, Thomssen C, Harbeck N, Wang L, Apple S, Jänicke F, Slamon DJ.
    Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985
    [Abstract] [Full Text] [Related]

  • 23. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
    Järvinen TA, Liu ET.
    Curr Cancer Drug Targets; 2006 Nov; 6(7):579-602. PubMed ID: 17100565
    [Abstract] [Full Text] [Related]

  • 24. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.
    Varga Z, Moelans CB, Zuerrer-Hardi U, Ramach C, Behnke S, Kristiansen G, Moch H.
    Breast Cancer Res Treat; 2012 Jun; 133(3):929-35. PubMed ID: 22083232
    [Abstract] [Full Text] [Related]

  • 25. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [Abstract] [Full Text] [Related]

  • 26. Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
    Hagen AI, Bofin AM, Ytterhus B, Maehle LO, Kjellevold KH, Myhre HO, Møller P, Lønning PE.
    Acta Oncol; 2007 Oct; 46(2):199-203. PubMed ID: 17453369
    [Abstract] [Full Text] [Related]

  • 27. Genetic alterations in ERBB2-amplified breast carcinomas.
    Isola J, Chu L, DeVries S, Matsumura K, Chew K, Ljung BM, Waldman FM.
    Clin Cancer Res; 1999 Dec; 5(12):4140-5. PubMed ID: 10632352
    [Abstract] [Full Text] [Related]

  • 28. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
    Murphy AJ, Hughes CA, Barrett C, Magee H, Loftus B, O'Leary JJ, Sheils O.
    Cancer Res; 2007 Mar 15; 67(6):2893-8. PubMed ID: 17363613
    [Abstract] [Full Text] [Related]

  • 29. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ.
    Clin Cancer Res; 2002 May 15; 8(5):1107-16. PubMed ID: 12006526
    [Abstract] [Full Text] [Related]

  • 30. A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening andtreatment.
    Hansel DE, Ashfaq R, Rahman A, Wanzer D, Yeo CJ, Wilentz RE, Maitra A.
    Am J Clin Pathol; 2005 Jan 15; 123(1):28-35. PubMed ID: 15762277
    [Abstract] [Full Text] [Related]

  • 31. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.
    Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD.
    Clin Cancer Res; 2002 Apr 15; 8(4):1061-7. PubMed ID: 11948114
    [Abstract] [Full Text] [Related]

  • 32. Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer.
    Rennstam K, Baldetorp B, Kytölä S, Tanner M, Isola J.
    Cancer Res; 2001 Feb 01; 61(3):1214-9. PubMed ID: 11221853
    [Abstract] [Full Text] [Related]

  • 33. Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts.
    Usha L, Tabesh B, Morrison LE, Rao RD, Jacobson K, Zhu A, Basu S, Coon JS.
    J Hematol Oncol; 2008 Aug 14; 1():12. PubMed ID: 18702822
    [Abstract] [Full Text] [Related]

  • 34. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours.
    Storlazzi CT, Brekke HR, Mandahl N, Brosjö O, Smeland S, Lothe RA, Mertens F.
    J Pathol; 2006 Aug 14; 209(4):492-500. PubMed ID: 16721726
    [Abstract] [Full Text] [Related]

  • 35. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS.
    Mod Pathol; 2000 May 14; 13(5):542-7. PubMed ID: 10824926
    [Abstract] [Full Text] [Related]

  • 36. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C, Bellet M, Fabregat X, Serrano S, Solé F.
    Breast Cancer Res; 2005 May 14; 7(2):R267-73. PubMed ID: 15743507
    [Abstract] [Full Text] [Related]

  • 37. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses.
    Bhargava R, Lal P, Chen B.
    Am J Clin Pathol; 2005 Jun 14; 123(6):889-95. PubMed ID: 15899781
    [Abstract] [Full Text] [Related]

  • 38. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIalpha genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization.
    Murthy SK, Magliocco AM, Demetrick DJ.
    Arch Pathol Lab Med; 2005 Jan 14; 129(1):39-46. PubMed ID: 15628907
    [Abstract] [Full Text] [Related]

  • 39. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.
    Nielsen KV, Ejlertsen B, Møller S, Jørgensen JT, Knoop A, Knudsen H, Mouridsen HT.
    Acta Oncol; 2008 Jan 14; 47(4):725-34. PubMed ID: 18465341
    [Abstract] [Full Text] [Related]

  • 40. Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.
    García-Caballero T, Prieto O, Vázquez-Boquete A, Gude F, Viaño P, Otero M, Curiel T, Fernández-Rodríguez B, Parrado C, Fraga M, Antúnez JR.
    Breast Cancer Res Treat; 2014 Jan 14; 143(1):81-9. PubMed ID: 24292870
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.